HUE032085T2 - Androgén receptor-modulátor prosztatarák és androgén receptorral kapcsolatos betegségek kezelésére - Google Patents

Androgén receptor-modulátor prosztatarák és androgén receptorral kapcsolatos betegségek kezelésére Download PDF

Info

Publication number
HUE032085T2
HUE032085T2 HUE13178051A HUE13178051A HUE032085T2 HU E032085 T2 HUE032085 T2 HU E032085T2 HU E13178051 A HUE13178051 A HU E13178051A HU E13178051 A HUE13178051 A HU E13178051A HU E032085 T2 HUE032085 T2 HU E032085T2
Authority
HU
Hungary
Prior art keywords
substituted
alkyl
aryl
alkenyl
compound
Prior art date
Application number
HUE13178051A
Other languages
English (en)
Inventor
Michael E Jung
Charles L Sawyers
Samedy Ouk
Chris Tran
John Wongvipat
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38656005&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE032085(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of HUE032085T2 publication Critical patent/HUE032085T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (5)

.4NP&ÔGÊ** 8£CSPTÖR*M0DüLÁTö8 PROSZTATARÁK MAÄÖÖäsN bstsgsIgek KÊZ6iêsêR£ •SZABADALMi IGÉNYPONTOK
1. Vegyül« s K^íis»Hlm
Kôpifji ií vagy sasak yyôgyszofésxsÂg sápadható sósa ans! Als iagyn>ss&amp;i &amp;gg&amp;8eo§^fpav^y k&amp;î kosa: kivè&amp;s#i8| sha; Ri sit îf3§SÎ$zubsïUiüâ!t ass! *όε&amp; kivâs&amp;Â;· Ä! Ét 'èsMa sss?îSSimmskg§yù5i^siiÎ:ame;y^K #fi#ài? **§? «m»***1 oé^é^M MM Ri M Rf és Éf 8gymástöFͧ|^8?íúi hidfisgèni. ha!ög#Ms1í *W. CN·?, Ä sajbs&amp;bèïl &amp;*% *»'*. Ä SZUb5Ââî'âi|:^^. mme®. h8i^s^ ***· âikîn!t bá^Ssmi *402-1 QB'H S»1R î^HRIH HH(CO)ORiU m<CQm'.m2-i NR^(C0)R11*t 0(C0p1 H. OlCOpKl% ÛiCSjRtH lÂpSfKtK ΝΗ(08}ΝΜ««2Ί «s «W2KfcjOftm îsr^miO kîvàîas?.îot», aboi R 11 As Ri 2 fegyítumoi iagyaifead hidrogén, m wtbsziuéSt Ä aikénii· sagy mosabiasu afeisagy aaafeatausk gadaii. ar« $M>sÄait «ai. antalfci aalsAansk anialkiAS!. neiÉôÂuséS: ætMè* ïiS'>l ν%1 halôf'X^iasos aîofn^s vagy aara aromás osopoft kö?.yi kivàsassfetg a*o! RH ès mi üe» mim® «ikosssnak amely me sayOsaîiiasRhsÉrxÀiaxs βκχ«*$ ceopori. aboi mindegy* awbssSu«? aik« egymás fü^ieniii sáskáit «gy vagy »ab ^opom^i bidfos·.· áram·, feox kló?*, jón-, m®kwte*> 8* daos-, emm-, heíerodkUmíh ank heteroarü-, ksf^Ä, J^bÄin *** *μ*&amp;**> a&amp;oxii· és sovclû-csopoRok kôzüi kiyáis&amp;löifóíX .mimtegyt* sxübsîfetuâH <$tom egymássöl íággsífcnöí sxaOaztrîoàit ogy *»·«» aiSï^sy-m^ s*», «ta»*», dK^âh aiMwfe.. sixanakamlno-. ^ a>;<k ao&amp;artoii-a^no-, *»"«-· m*. htm-, «uor-, Môr-. yxh Ww**·· tabwcil· xa^kdk &amp;m\- &amp;% ar*d*ssopo«iok mmmtrnmi rém?* szafesrM aíkeM egedéi *0**«* s?«fes&amp;« agi *oáy bob caoponiss Ä **<»*. nm*» m* ash «skaM-aw. a*«»·. *&amp;<>- asR°··ï!oK 8lNiK5'· fcrènk ibor-, fôr~ £d·, xraax^sov, hetetöabh feto*. karb&amp;koik aikeml- èa amáo-asopoook ΚυΛ! î v«:«s*.u.-,ba. a'iîajogysk siubsaitüät atN «gyrrèsid ^g^o8««uï ykaxtísbaíl í?gy s%y bbo !ovyX'>«is . , ^ säfekä. siddka-, .'.:käo;^a «&amp;·^··>>φ d'^ie^nv -ho- a'X o<'!skafb>a';-af^w'io·' 3!i,,sVi'' o>s«·. tfv' \v κό siy K “ x" ^ ^ oe< 'k' K5’ nsíndegylx sMbspiioèi? 3d! «gynpstö; IpgeOahi:; szufcwëfeâlf ffif# ®êm&amp;>> m- W^Ä ..i,si . χ^Ο'-' 3' I* feu (''«ÎO'Î tM'5,- OvdoM&amp; OAv'Skx'lk^K e^SeXXvC-ae.: iW , insæroani-, eèPaRv anioxk aPoiaikl- edkPoV-. a&amp;oxikaiôonil·. pnikedxtnî af^kena-, agnno-xgslxsnítaoh «np-, anisailfasi-, Sülftzo··. nstef03i:i-aik;i'. ΡδΙ^οοηΙ^ίΜηιΟ. hsProedi-osRnoariK hetsfo-anioxi-, bidroxe nitro-. e<ano-, stninov szvosxMaPt amino- nket sït asnmocs^pofí l&amp;ftüífnax 1 vagy 2 exubaxtaaefis· (ameiy^k alk«-, «η-. 3n\!tki;-. anenkefai-, anlatkim!-. hetsfoant·, anks«., enkes-atK*?- jsíila^ori-. «nikitxevj- sdlalkenk snxnokastx^saeh aalfcon «nlveiflnn. ansa?ö-s haiefoent-atki;-. hotsKwä-aikenä-. neteroafll-hepfosdl·. heknoani-oxi· hefcfosnMiíx arnfio-sikîK aikoxt-sotks-, snisntsnsx karbonit-. arüwöonü-öxs-. eniksitx^.-aroimy, antsswifiwk atfntl·-ait·'.. aotezaron-i-asrsnö- vagy ar:í§ru::för;-aieinokanxniii-csepoft). karmák aikii-Kaitiamol- anséissn msstxAk araiddreii k8?O0*i»fksi\ aikJ sm^ïM karboxialkä. Sok alkusé-, snffcv haferoani-ho-, sílltsö-aiiók «IkeWst-eo· alkitkarbonik ehlkeitxsn*·. akfeonno-kaiSon«-. aótamino-ka?b«oíh í#iO>sksdssnsk aoenokastsorsk . aiMkaroanth©*}*,. iätöksrsösibs&amp;t?,: afakatbsaai-atnind'·,. apsÄntk a$§ziÄ#-a!K&amp; adisxiijdeoksmieo:. hatarsiôkkjfcôs*. ^φο*ϊ·. karhatkcB- as arcade esendők käti ktváisssAP: ès mindegyik sxubsxtituái! heieroökksns popart egynsMki függetlenéi SÂibsatuâl! «gy-n«gy csoportiéi aikik sikoxh hidioxk ;ar8-;:Äyk Msikih. ^kSo^liK; K^lfetlâiïs^ri aîKanoiâaîïi s-no-, oxee, aol-, ixtik oboákén neo·. «rcuno«·, n‘tex tæaoo-, soi-, alkltie-: erőm-·, Saor-, ktbr-, j&amp;k heterociklusos-. hateroarik ka&amp;oxik Mihaiknk sisnk èl:arcàdiCSopom>k Mxfii kiválasztottén.
2 Vegyidet 32t· es prcypom szedni, vagy annsk gvSgyszetôsxstiieg eifcgsdhatô sÓp aboi Ajeseriése Μη.
3 Vegyi!»: ez. 1~e$ vagy 2-es Igénypont ssetlnt. vagy annak gyêgy^èaze$ag.eÉag«db3!6. §ój&amp; nnoi 8 jelentése o&amp;gèni
4 Vegyidet sz 1-lét 3-<9 igénypontok béoneiyfke szennt vagy annakgÿdgyszetessehleg elfogadható sója, ahc! Ri jslerctese -axuosÂaîvteat'
5. Vegyütet az t-töt 3-¾ Igénypontok bárcnelyiM szene!. vagy annak gy6gy$at^g(i^;;#^S$!§-^|<::Í^I Rijphise: S2abs3staät tank ahoi az «nfifau h*ê szabsztMsh agy vagy több osyarc cs&amp;poíisl, apépl fiSS -oÿ?, Sv. aoo : xO X- V t f0^ n;v v^-· -1 ^ cg a'k'P^f d<* -3 t a>' 1 R2 Os l- ' - νΛ'Ρ> '.Μ·)ΑΙΑΙ X Ok!íí.0x\3kak3ZvA 'οΚ'!\- δ. Vegyük»! aa ecidsgl igénypontok bàfmalyike scannt, vagy annak gypys.î&amp;rèbzakkrg aipadkaló köp ahol Rk es R3 a iMn aMntnsi 5 Vegye!« ax %óű=gi kpsnpontek hanoeiy^s ss^int. vagy annak gyógys-ee-és^ab^g elfogadható sola, ahoi R4 CN-f es vv-2-ϊ -anaSTssye οβ-^ιοΟχ ^v<Vaestott Rè kV^aíegé-evtett ax-ï xve'k fsfke'«it nskg-^ erev a«r u? halogének«! tadaknayé osiexektp! kivéi«sz!oü ès P8 és R? «gym^ független«! tndêx:éntf alknt es hidrogénből fhdaipttp gsdppóillypgpóli ': : Vágyó!«! as S·«?, poypo-4 szedrd. vagy annak gyègysseièssetteg ekogaöhPá ?óia BS tnf^o>· n etse .V5> r>d=<iot Pile '' êA i'SvO'Rkn Nvaaee: r t-c >·ρ er ' yj> '"'-‘r kgee^·-·" ne^s“ *v 1 ^\e «Rk * f '^.e -,v.\ Ré klvólBaztij;!. 11 Vegyeieí a? eddigi igènyponîek bsieieiyiKe sseent. vagy annak gyôgyszsréizahkg eílogadható sója gyógyazetkéní tódónö felhasknáiósbsn ¢. 12 Vegyöfcl az U&amp; 10-p Ipnypontok gonnetyiRs m ^pâtérsgèhan se ?donógassa j&amp;ó »endPlovesseg kezelésein Ιό?|ρό;%Ιό3δΖί·ι akvsnsn. Ill .......’ :f r: : 1 ;1. : :: j ill III jjj jjj if! j j if I fîlÎ! Jll fii til If- ||| il ^ é <5 Í j ! !;ill; i '1 Ί :| I # i ! -.1 J ^ I 1¾ I
HUE13178051A 2006-03-27 2007-03-27 Androgén receptor-modulátor prosztatarák és androgén receptorral kapcsolatos betegségek kezelésére HUE032085T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78597806P 2006-03-27 2006-03-27
US83379006P 2006-07-28 2006-07-28

Publications (1)

Publication Number Publication Date
HUE032085T2 true HUE032085T2 (hu) 2017-09-28

Family

ID=38656005

Family Applications (6)

Application Number Title Priority Date Filing Date
HUE07754060A HUE027894T2 (hu) 2006-03-27 2007-03-27 Androgén receptor modulátor a prosztatarák és az androgén receptorral összefüggõ betegségek kezelésében
HUE13178047A HUE031079T2 (hu) 2006-03-27 2007-03-27 Androgén receptor-modulátor prosztatarák és androgén receptorral kapcsolatos betegségek kezelésére
HUE13178051A HUE032085T2 (hu) 2006-03-27 2007-03-27 Androgén receptor-modulátor prosztatarák és androgén receptorral kapcsolatos betegségek kezelésére
HUE18181743A HUE053877T2 (hu) 2006-03-27 2007-03-27 Androgén receptormodulátor a prosztatarák és az androgén receptorral összefüggõ betegségek kezeléséhez
HUE16173574A HUE042037T2 (hu) 2006-03-27 2007-03-27 Androgén receptormodulátor a prosztatarák és az androgén receptorral összefüggõ betegségek kezeléséhez
HUS1900030C HUS1900030I1 (hu) 2006-03-27 2019-05-22 Androgén receptor modulátorok a prosztatarák és androgén receptorral összefüggõ betegségek kezelésére

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HUE07754060A HUE027894T2 (hu) 2006-03-27 2007-03-27 Androgén receptor modulátor a prosztatarák és az androgén receptorral összefüggõ betegségek kezelésében
HUE13178047A HUE031079T2 (hu) 2006-03-27 2007-03-27 Androgén receptor-modulátor prosztatarák és androgén receptorral kapcsolatos betegségek kezelésére

Family Applications After (3)

Application Number Title Priority Date Filing Date
HUE18181743A HUE053877T2 (hu) 2006-03-27 2007-03-27 Androgén receptormodulátor a prosztatarák és az androgén receptorral összefüggõ betegségek kezeléséhez
HUE16173574A HUE042037T2 (hu) 2006-03-27 2007-03-27 Androgén receptormodulátor a prosztatarák és az androgén receptorral összefüggõ betegségek kezeléséhez
HUS1900030C HUS1900030I1 (hu) 2006-03-27 2019-05-22 Androgén receptor modulátorok a prosztatarák és androgén receptorral összefüggõ betegségek kezelésére

Country Status (20)

Country Link
US (6) US8445507B2 (hu)
EP (8) EP2368550B1 (hu)
JP (10) JP5133975B2 (hu)
CN (1) CN101454002B (hu)
AU (1) AU2007243651C1 (hu)
BR (1) BRPI0709771B1 (hu)
CY (7) CY1114623T1 (hu)
DK (6) DK2368550T3 (hu)
ES (6) ES2564388T7 (hu)
FI (1) FI2004181T6 (hu)
HK (4) HK1126421A1 (hu)
HU (6) HUE027894T2 (hu)
LT (5) LT2656842T (hu)
LU (1) LUC00123I2 (hu)
NL (1) NL300993I2 (hu)
NZ (1) NZ572335A (hu)
PL (6) PL2368550T3 (hu)
PT (5) PT3412290T (hu)
SI (6) SI2368550T1 (hu)
WO (1) WO2007126765A2 (hu)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007514442A (ja) 2003-12-19 2007-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 前立腺癌治療を評価するための方法および物質
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
PL2368550T3 (pl) 2006-03-27 2014-01-31 Univ California Modulator receptorów androgenowych do leczenia raka gruczołu krokowego i chorób związanych z receptorami androgenów
EP2439196A1 (en) 2006-03-29 2012-04-11 The Regents of The University of California Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
CA2966280A1 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
FR2944524B1 (fr) * 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
KR101456994B1 (ko) * 2009-09-10 2014-11-04 통유지 안드로겐 수용체 길항제 및 그의 용도
ES2575215T3 (es) 2009-12-11 2016-06-27 Autifony Therapeutics Limited Derivados de imidazolidindiona
JP5702595B2 (ja) * 2009-12-25 2015-04-15 石原産業株式会社 2−クロロ−3−トリフルオロメチルピリジンの製造方法
AU2016208310B2 (en) * 2010-02-16 2017-10-05 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
AU2014271290C1 (en) * 2010-02-16 2016-10-27 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP3124481B1 (en) * 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
ES2880354T3 (es) 2010-02-24 2021-11-24 Medivation Prostate Therapeutics Llc Procesos para la síntesis de compuestos de diariltiohidantoína y diarilhidantoína
DK2649066T3 (en) 2010-12-06 2016-01-11 Autifony Therapeutics Ltd Hydantoin derivatives using as KV3 inhibitors.
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
JP6158180B2 (ja) 2011-07-29 2017-07-05 メディベイション プロステイト セラピューティクス, インコーポレイテッド 乳がんの処置
US9708276B2 (en) 2011-10-12 2017-07-18 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
WO2013056547A1 (zh) * 2011-10-22 2013-04-25 Chen Degui 一组乙内酰脲衍生物的合成及其应用
CN103159680A (zh) 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
UY34646A (es) 2012-03-02 2013-10-31 Novartis Ag Compuestos de espirohidantoína y su uso como moduladores selectivos del receptor de andrógenos
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
EP2852588B8 (en) 2012-05-22 2018-01-10 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
CN104334547B (zh) 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
JP6182209B2 (ja) 2012-06-07 2017-08-16 アラゴン ファーマシューティカルズ,インコーポレイテッド アンドロゲン受容体変調剤の結晶質形態
CN105358535B (zh) 2012-09-11 2019-01-04 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
CA2885415C (en) 2012-09-26 2021-06-29 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
AU2013334102B2 (en) 2012-10-26 2018-08-16 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP3020714B1 (en) 2013-05-29 2022-12-28 Hinova Pharmaceuticals Inc. Imidazole diketone compound and use thereof
WO2015018356A1 (zh) * 2013-08-08 2015-02-12 上海医药集团股份有限公司 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
EP3046556A4 (en) * 2013-09-19 2017-04-26 Glaxosmithkline LLC Combination drug therapy
US10882834B2 (en) 2013-09-20 2021-01-05 University of Pittsburgh—of the Commonwealth System of Higher Education Compounds for treating prostate cancer
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
CN103601671B (zh) * 2013-10-22 2016-08-17 上海泰坦科技股份有限公司 碘代三氟甲基吡啶的制备方法
ES2725881T3 (es) 2013-12-31 2019-09-30 Ipsen Pharma Sas Nuevos derivados de imidazolidin-2,4-diona
MX2016010604A (es) 2014-02-14 2017-04-27 Univ British Columbia Compuestos de dominio de unión a ácido desoxirribonucleico (dbd a adn) del receptor de andrógeno humano como terapéuticos, y métodos para su uso.
CN104003939B (zh) * 2014-06-06 2017-07-07 山东大学 二芳基取代乙内酰硫脲类化合物及其制备方法与应用
WO2015196144A2 (en) 2014-06-20 2015-12-23 England Pamela M Androgen receptor antagonists
ES2883187T3 (es) 2014-12-05 2021-12-07 Aragon Pharmaceuticals Inc Composiciones anticancerosas
JP6767368B2 (ja) * 2014-12-05 2020-10-14 アラゴン ファーマシューティカルズ,インコーポレイテッド 抗癌性組成物
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
BR112017012142A2 (pt) 2014-12-12 2018-01-02 Medivation Prostate Therapeutics Inc método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama
LT3233823T (lt) * 2014-12-19 2019-04-10 Aragon Pharmaceuticals, Inc. Diariltiohidantoino junginio gamybos būdai
LT3233803T (lt) * 2014-12-19 2019-04-10 Aragon Pharmaceuticals, Inc. Diariltiohidantoino junginio gamybos būdas
CN105732575A (zh) * 2015-02-06 2016-07-06 苏州晶云药物科技有限公司 一种治疗前列腺癌的新型抗雄激素类药物的新晶型及其制备方法
WO2016141458A1 (en) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
CA3036011A1 (en) * 2016-08-20 2018-03-01 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
CN107954936B (zh) * 2016-10-17 2021-03-19 海创药业股份有限公司 一种制备氘代咪唑二酮类化合物的方法
CN108069869B (zh) * 2016-11-09 2022-03-01 上海医药工业研究院 一种Apalutamide的制备方法及其中间体
RU2019121700A (ru) 2016-12-13 2021-01-15 Ватсон Лэборетериз Инк. Твердые формы апалутамида
CA3049443A1 (en) 2017-01-11 2018-07-19 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
TW201831461A (zh) * 2017-01-18 2018-09-01 台灣神隆股份有限公司 製備阿帕魯醯胺的方法
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
AU2018314980B2 (en) 2017-08-07 2022-05-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Diarylthiohydantoin compound as androgen receptor antagonist
JP7158393B2 (ja) 2017-09-14 2022-10-21 第一三共株式会社 環状構造を有する化合物
EP3697398A1 (en) 2017-10-16 2020-08-26 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN108047200A (zh) * 2017-12-05 2018-05-18 上海丰瑞医药科技有限公司 一种二芳基乙内酰硫脲类化合物的制备方法及其中间体
CN108003093A (zh) * 2017-12-07 2018-05-08 山东汇盟生物科技有限公司 2-羟基-3-三氟甲基吡啶的制备方法
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
CN109988077A (zh) * 2017-12-29 2019-07-09 上海法默生物科技有限公司 一种阿帕鲁胺的合成方法及中间体
WO2019135254A1 (en) 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
US10934269B2 (en) * 2018-03-28 2021-03-02 Cadila Healthcare Limited Process for preparation of apalutamide
US10807965B2 (en) * 2018-03-28 2020-10-20 Cadila Healthcare Limited Process for preparation of apalutamide
CN108314646B (zh) * 2018-04-11 2021-03-19 武汉慧敏科技中心 一种高分散双金属纳米材料制备泌尿生殖系统用药物中间体的方法
CN108311155B (zh) * 2018-05-14 2020-11-06 上海奥萝拉医药科技有限公司 一种催化制备治疗前列腺癌症药物阿帕鲁胺中间体的方法
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
US20200270226A1 (en) 2018-06-20 2020-08-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of arn-509, preparation method and use thereof
CN108976171B (zh) * 2018-08-27 2020-06-16 长沙泽达医药科技有限公司 化合物、组合物及其在药物制备中的用途
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
JP2022509917A (ja) 2018-11-05 2022-01-25 ファイザー・インク がんを処置するための組合せ
WO2020113088A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
CA3128331A1 (en) 2019-01-30 2020-08-06 Margaret K. YU Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020198710A1 (en) * 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
IT201900010593A1 (it) 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
US20210038578A1 (en) 2019-08-08 2021-02-11 Laekna Limited Method of treating cancer
WO2021033098A1 (en) * 2019-08-22 2021-02-25 Dr. Reddy’S Laboratories Limited Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
AU2021255723A1 (en) 2020-04-17 2022-12-08 Essa Pharma, Inc. Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
JP2023537595A (ja) 2020-08-13 2023-09-04 ファイザー・インク 併用治療
EP4208451A1 (en) 2020-09-04 2023-07-12 Synthon B.V. Improved process for preparation of apalutamide
CN114621184B (zh) * 2020-12-10 2024-04-26 奥锐特药业股份有限公司 一种阿帕他胺的制备方法
MX2023011294A (es) 2021-03-24 2023-10-05 Pfizer Combinacion de talazoparib y un antiandrogeno para el tratamiento del cancer de prostata sensible a la castracion metastasico mutado en el gen ddr.
WO2024074959A1 (en) 2022-10-02 2024-04-11 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2024088395A1 (zh) * 2022-10-28 2024-05-02 南京明德新药研发有限公司 桥环类化合物及其在药学上的应用
WO2024102706A1 (en) * 2022-11-09 2024-05-16 Bristol-Myers Squibb Company Combination therapy with substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds
WO2024121163A1 (en) 2022-12-06 2024-06-13 Cancer Research Technology Limited Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE550650A (hu) 1955-08-30
US3823240A (en) 1970-10-06 1974-07-09 Rhone Poulenc Sa Fungicidal hydantoin derivatives
GB1472467A (en) 1974-04-19 1977-05-04 Wyeth John & Brother Ltd Thiohydantoins
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE2614831A1 (de) * 1976-04-06 1977-10-20 Bayer Ag 1,3,4-thiadiazolylderivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
CA1138334A (en) 1977-10-28 1982-12-28 Karl Bernauer Pharmaceutical preparations containing certain urea derivatives
MC1220A1 (fr) 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
ZA786739B (en) 1977-12-01 1980-07-30 Wellcome Found Hydantoin derivatives and salts thereof,their syntheses,and intermediates,and pharmaceutical formulations
EP0004723A1 (en) 1978-03-30 1979-10-17 Beecham Group Plc Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them
FR2449448B1 (fr) 1979-02-20 1983-05-27 Inst Nat Radio Elements Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation
FI801184A (fi) 1979-04-24 1980-10-25 Hoffmann La Roche Foerfarande foer framstaellning av imidazolidinderivat
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0070613A3 (en) * 1981-05-08 1984-05-09 Ace Coin Equipment Limited Video gaming or amusement machine
JPS57197268A (en) 1981-05-29 1982-12-03 Sumitomo Chem Co Ltd Substituted phenylhydantoin derivative, its preparation, and herbicide containing the same as active ingredient
DE3382406D1 (de) 1982-04-08 1991-10-17 Shell Int Research Neue hydantoine, ihre herstellung und verwendung.
US4473393A (en) 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
JPS59210083A (ja) * 1983-05-13 1984-11-28 Otsuka Chem Co Ltd 1,3,4−チアジアゾ−ル−5−オン誘導体、その製造法及び該誘導体を有効成分とする除草剤
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS6092285A (ja) * 1983-10-26 1985-05-23 Shionogi & Co Ltd イソオキサゾ−ル系環状尿素類
JPS60239737A (ja) * 1984-05-14 1985-11-28 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
DE3604042A1 (de) 1986-02-08 1987-08-13 Hoechst Ag Imidazolidin(thi)on-derivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
JPS649978A (en) * 1987-07-02 1989-01-13 Shionogi & Co Perfluoroalkylisoxazole derivative
US4859228A (en) 1987-07-16 1989-08-22 Ici Americas Inc Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
FR2619381B1 (fr) 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
CA1331757C (en) 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5614620A (en) 1988-03-30 1997-03-25 Arch Development Corporation DNA binding proteins including androgen receptor
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US6307030B1 (en) 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE3835168A1 (de) 1988-10-15 1990-04-19 Bayer Ag N-aryl-stickstoffheterocyclen, mehrere verfahren zu ihrer herstellung und ihre verwendung als herbizide
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
FR2656302B1 (fr) 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
JP2845384B2 (ja) 1991-11-14 1999-01-13 キヤノン株式会社 画像処理装置
US5346913A (en) 1992-05-26 1994-09-13 Rohm And Haas Company N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2715402B1 (fr) 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
JPH09508125A (ja) 1994-01-21 1997-08-19 セプラコー,インコーポレイテッド 光学的純正r−(−)−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成
JPH089997A (ja) 1994-06-28 1996-01-16 Shimadzu Corp 核酸合成法およびそれに用いる試薬キット
EP0721944B1 (en) 1994-07-29 2001-01-17 Suntory Limited Imidazolidine derivative and use thereof
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
FR2741346B1 (fr) 1995-11-16 1997-12-19 Roussel Uclaf Nouveau procede de preparation de derives phenylimidazolidine
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
EP0876354A1 (en) 1995-11-28 1998-11-11 American Home Products Corporation 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives
TW418195B (en) * 1995-11-28 2001-01-11 American Home Prod 2-thioxo-imidazolidin-4-one derivatives
US5554607A (en) 1995-11-28 1996-09-10 American Home Products Corporation Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
FR2742749B1 (fr) 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
US6489163B1 (en) 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
JP3697320B2 (ja) 1996-06-20 2005-09-21 株式会社日立製作所 光ファイバセンサ
US5726061A (en) 1996-10-08 1998-03-10 Smithkline Beechum Corporation Method of diagnosing and monitoring colorectal cancer
US7053263B2 (en) 1996-10-15 2006-05-30 The Regents Of The University Of California Mouse models of human prostate cancer progression
US6506607B1 (en) 1997-12-24 2003-01-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
AU4562799A (en) * 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE69938005T2 (de) 1998-09-22 2009-01-15 Astellas Pharma Inc. Cyanophenyl-derivate
ATE240944T1 (de) 1998-09-22 2003-06-15 Degussa Verfahren zur herstellung von imidazolidin-2,4- dionen
AU1308400A (en) * 1998-10-30 2000-05-22 G.D. Searle & Co. Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
WO2000044731A1 (en) 1999-01-27 2000-08-03 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
WO2001007048A1 (en) * 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6479063B2 (en) 1999-12-27 2002-11-12 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
MXPA02011858A (es) * 2000-05-31 2004-07-30 Tanabe Seiyaku Co Inhibidores de adhesion de celula mediada por alfabeta2.
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
WO2002053155A1 (en) 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
FR2823209B1 (fr) * 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
CA2462112A1 (en) 2001-10-01 2003-04-10 Bristol-Myers Squibb Company Spiro-hydantoin compounds useful as anti-inflammatory agents
WO2003032994A2 (de) * 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
GB0200283D0 (en) 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
DE10218963A1 (de) 2002-04-27 2003-11-20 Aventis Pharma Gmbh Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
EP1576131A4 (en) 2002-08-15 2008-08-13 Genzyme Corp EXPRESSION PATTERN IN BRAIN DENTHELIC CELLS
AU2002951247A0 (en) * 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
FR2845384B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2845385B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
JP2006504795A (ja) * 2002-10-03 2006-02-09 サイプレス バイオサイエンス, インコーポレイテッド 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
JP2006510600A (ja) 2002-10-04 2006-03-30 ラボラトワール フルニエ エス・アー 2−チオヒダントインに由来する化合物及び治療におけるその使用
UA79504C2 (en) 2002-11-07 2007-06-25 Organon Nv Indols for treating diseases associated with androgen receptors
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
AU2004247319A1 (en) * 2003-06-12 2004-12-23 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
US7271188B2 (en) 2003-06-12 2007-09-18 Chugai Seikayu Kabushiki Kaisha Imidazolidine derivatives
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
WO2005059109A2 (en) 2003-12-15 2005-06-30 The Regents Of The University Of California Molecular signature of the pten tumor suppressor
JP2007514442A (ja) 2003-12-19 2007-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 前立腺癌治療を評価するための方法および物質
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US8940896B2 (en) * 2004-03-15 2015-01-27 Ptc Therapeutics, Inc. Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis
DE602004008874T2 (de) * 2004-03-18 2008-06-12 Bt Pharma Rekombinante Proteine, die Epitope des humanen Papillomavirus inseriert in einem Adenylatecyclase Protein oder in dessen Fragmenten tragen, und deren terapeutischen Verwendung.
EP1621536A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621539A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
TW200612920A (en) 2004-08-03 2006-05-01 Chugai Pharmaceutical Co Ltd Novel imidazolidine derivatives
TW200621723A (en) 2004-09-09 2006-07-01 Chugai Pharmaceutical Co Ltd Novel imidazolidine derivative and use thereof
DK1893196T4 (en) * 2005-05-13 2015-10-19 Univ California Diarylhydantoin connection
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
PL2368550T3 (pl) 2006-03-27 2014-01-31 Univ California Modulator receptorów androgenowych do leczenia raka gruczołu krokowego i chorób związanych z receptorami androgenów
EP2439196A1 (en) 2006-03-29 2012-04-11 The Regents of The University of California Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins

Also Published As

Publication number Publication date
PL2004181T6 (pl) 2023-09-04
HUE027894T2 (hu) 2016-11-28
ES2689292T3 (es) 2018-11-13
LT2656842T (lt) 2016-09-26
US8802689B2 (en) 2014-08-12
EP3100727A1 (en) 2016-12-07
PL2656842T3 (pl) 2017-01-31
HK1190928A1 (zh) 2014-07-18
ES2588606T3 (es) 2016-11-03
LT2656841T (lt) 2016-09-26
DK2656841T3 (en) 2016-12-05
JP6027662B2 (ja) 2016-11-16
JP7257692B2 (ja) 2023-04-14
ES2428291T3 (es) 2013-11-06
CY1117540T1 (el) 2017-04-26
LUC00123I1 (hu) 2019-06-06
PL2656841T3 (pl) 2017-01-31
EP3412290A1 (en) 2018-12-12
EP2656842B1 (en) 2016-08-10
DK2004181T6 (da) 2023-08-21
DK2368550T3 (da) 2013-09-30
EP2004181B1 (en) 2016-02-24
CY1117958T1 (el) 2017-05-17
ES2863798T3 (es) 2021-10-11
DK3100727T3 (en) 2018-11-12
JP2023001259A (ja) 2023-01-04
SI2656842T1 (sl) 2016-10-28
SI2656841T1 (sl) 2016-11-30
EP2004181A2 (en) 2008-12-24
PL2004181T3 (pl) 2016-06-30
HUS1900030I1 (hu) 2020-04-28
LTPA2019512I1 (lt) 2019-07-25
BRPI0709771A2 (pt) 2011-07-26
SI2368550T1 (sl) 2013-11-29
US9987261B2 (en) 2018-06-05
PT3412290T (pt) 2021-04-19
CN101454002A (zh) 2009-06-10
HK1126421A1 (zh) 2009-09-04
PT2656841T (pt) 2016-09-28
CY1118026T1 (el) 2017-05-17
WO2007126765A2 (en) 2007-11-08
EP2656841A1 (en) 2013-10-30
PT2656842T (pt) 2016-10-04
PL2368550T3 (pl) 2014-01-31
AU2007243651C1 (en) 2013-03-14
EP2368550B1 (en) 2013-09-04
DK2656842T3 (en) 2016-11-07
US8445507B2 (en) 2013-05-21
JP6057518B2 (ja) 2017-01-11
US20180318276A1 (en) 2018-11-08
SI3412290T1 (sl) 2021-09-30
JP2012092149A (ja) 2012-05-17
LUC00123I2 (hu) 2019-12-27
US9388159B2 (en) 2016-07-12
EP2004181B3 (en) 2023-05-24
ES2564388T3 (es) 2016-03-22
AU2007243651B2 (en) 2012-08-30
JP2016011315A (ja) 2016-01-21
WO2007126765A3 (en) 2008-11-06
US20110003839A1 (en) 2011-01-06
SI3100727T1 (sl) 2018-11-30
PT2368550E (pt) 2013-12-03
PT3100727T (pt) 2018-11-09
EP3835294A1 (en) 2021-06-16
EP3100727B1 (en) 2018-08-22
EP3412290B1 (en) 2021-03-03
HUE031079T2 (hu) 2017-06-28
CY2019028I2 (el) 2019-11-27
CN101454002B (zh) 2011-06-08
FI2004181T6 (fi) 2023-09-01
NZ572335A (en) 2011-09-30
EP4385574A2 (en) 2024-06-19
DK2004181T3 (en) 2016-04-25
EP2656841B1 (en) 2016-08-10
EP2368550A1 (en) 2011-09-28
HK1163495A1 (en) 2012-09-14
ES2593379T3 (es) 2016-12-09
JP2018065879A (ja) 2018-04-26
AU2007243651A1 (en) 2007-11-08
JP2020193234A (ja) 2020-12-03
EP2004181A4 (en) 2010-11-10
LT3100727T (lt) 2018-12-10
PL3412290T3 (pl) 2021-09-06
JP2016014069A (ja) 2016-01-28
US20140309262A1 (en) 2014-10-16
JP2019081815A (ja) 2019-05-30
LTC2368550I2 (lt) 2020-01-10
LT3412290T (lt) 2021-04-26
US10857139B2 (en) 2020-12-08
JP2014133755A (ja) 2014-07-24
JP2009531439A (ja) 2009-09-03
PL3100727T3 (pl) 2019-01-31
ES2564388T7 (es) 2023-12-21
BRPI0709771B1 (pt) 2022-01-25
US20130072511A1 (en) 2013-03-21
JP6701237B2 (ja) 2020-05-27
US11771687B2 (en) 2023-10-03
CY1114623T1 (el) 2016-10-05
NL300993I2 (nl) 2019-07-11
CY2019028I1 (el) 2019-11-27
HUE053877T2 (hu) 2021-07-28
HUE042037T2 (hu) 2019-06-28
HK1231375A1 (zh) 2017-12-22
CY1120828T1 (el) 2019-12-11
JP6422519B2 (ja) 2018-11-14
US20210121450A1 (en) 2021-04-29
JP2017105845A (ja) 2017-06-15
DK3412290T3 (da) 2021-04-19
SI2004181T1 (sl) 2016-07-29
EP2656842A3 (en) 2014-04-02
JP5133975B2 (ja) 2013-01-30
US20170014399A1 (en) 2017-01-19
EP2656842A2 (en) 2013-10-30
CY1124147T1 (el) 2022-05-27

Similar Documents

Publication Publication Date Title
US11771687B2 (en) Substituted diazaspiroalkanes as androgen receptor modulators
AU2018241101B2 (en) Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2012241184B2 (en) Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
AU2013205325B2 (en) Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases